Novaswitch by Novaptech
Novaptech selects, characterizes, optimizes and functionalizes aptamers for your project, whatever the type of target. Following the evaluation of the feasibility of your project, we run several positive and negative steps of selection under conditions compatible with your assay. The selection of NOVAswitches is carried out with targets FREE in solution. No need to synthesize analogs for immobilization on a solid support. No risk to generate aptamers against the linker. The target molecule used for NOVAswitch selection is the same as the one to be detected in your assay. The process for NOVAswitch selection relies on a structural change occurring upon binding to the target. This reduces the risk of selecting sequences binding to the support. The structural change is secondarily exploited for signalling the presence of the target molecule. This makes easier the design of aptamer-based assays and aptasensors. Just mix NOVAswitch and your sample and read! Novaptech offers different formats for optical signalling with NOVAswitches.
Merry Christmas & Happy New Year
Throughout the year we, at Novaptech managed to achieve goals and reach milestones thanks to our dedication and to the support of our customers, partners and Suppliers ! We would like to thank you for the collaboration we had this year and share with you some of our 2022 major achievements ! NOVAswitches, structure switching aptamers for a series of fungicides, and NOVAssays for their detection by fluorescence or colorimetry are available. Novaptech signed a license with Pure Biologics for the development of nucleotide-modified aptamers. Novaptech is a partner for 2 Horizon Europe “Farm to Fork” projects dealing with animal health. Novaptech participated in several on sites events, namely EU-Japan Biotech & Pharma Partnering Conference 2022 in Osaka, BioJapan in Yokohama as member of the EU-Japan Centre Biotech Mission, and BioFit in Strasbourg. More exciting news to come early 2023 !So stay tuned and follow us on our social networks ! Hoping to meet you and contribute to your innovative projects next year ! BEST WISHES !
A NOVAswitch aptamer to detect a pesticide
The need to detect residues of pesticides in food and water is of utmost importance for protecting the human health and the surrounding environment. Novaptech selected and characterized aptamers to thiabendazole, a fungicide used post- or pre-harvest for fruits (citrus, bananas, …) and vegetables (witloof, sweet potatoes, …). The 38 nt-long optimized DNA aptamer BOL009 was converted in a NOVAswitch sensor for the quantitative detection of this pesticide by fluorescence.
Novaptech regional winner of iLab 2017 contest !
i-Lab: National contest dedicated to innovative companies. Co-organised by Bpifrance and the Ministère de l’Enseignement supérieur, de la Recherche et de l’Innovation, i-LAB supports R&D programs of the best innovative projects. Novaptech was one of the Nouvelle Aquitaine regional winners in 2017.
Novaptech, un projet labellisé par Matwin et une recommandation positive du Board
Doser des biomarqueurs en temps réel, au chevet du patient ? Novaptech vous apporte une solution : les aptamères ! La médecine personnalisée est l’un des grands enjeux de santé publique. Elle s’accompagne entre autre de la nécessité de développer des dispositifs « point-of-care » pour un diagnostic au chevet du malade, des tests pour du diagnostic compagnon et des outils permettant un adressage ciblé des thérapeutiques. Les aptamères, molécules synthétiques de propriétés équivalentes à celles des anticorps, apportent des réponses innovantes à ces besoins. Novaptech est une jeune start-up bordelaise experte dans le domaine des aptamères. Novaptech développe des biocapteurs, c’est-à-dire des dispositifs signalant la présence de molécules recherchées, qui combinent des caractéristiques non adressées avec les méthodes actuelles : portabilité (pour des analyses au chevet du patient), rapidité (tests en temps réel), simplicité d’utilisation (pas de nécessité de personnel qualifié) et détections multiples simultanées. Grâce à son programme de R&D et sa technologie brevetée, Novaptech proposera prochainement des biocapteurs innovants – ou aptasenseurs – pour du diagnostic rapide et des tests compagnons permettant de détecter et de quantifier des biomarqueurs, des métabolites et des médicaments. >> Download the full article in french here
EN 
FR